AstraZeneca PLC (LON:AZN) Receives £145.83 Average Target Price from Brokerages

AstraZeneca PLC (LON:AZN) has received an average recommendation of “Moderate Buy” from the six brokerages that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is £145.83.

Several research analysts recently commented on the company. Citigroup began coverage on AstraZeneca in a research report on Tuesday, January 27th. They issued a “buy” rating and a £170 price target for the company. Berenberg Bank upped their price objective on AstraZeneca from £145 to £160 and gave the company a “buy” rating in a research report on Tuesday, January 27th. Shore Capital Group reaffirmed a “buy” rating on shares of AstraZeneca in a research note on Friday, January 16th. JPMorgan Chase & Co. reiterated an “overweight” rating on shares of AstraZeneca in a report on Thursday, January 15th. Finally, Deutsche Bank Aktiengesellschaft boosted their target price on AstraZeneca from £105 to £110 and gave the company a “sell” rating in a research report on Thursday, January 15th.

AstraZeneca Stock Performance

AstraZeneca stock opened at £138.90 on Wednesday. The company’s 50-day moving average price is £144.06 and its 200-day moving average price is £134.24. The company has a quick ratio of 0.59, a current ratio of 0.94 and a debt-to-equity ratio of 60.87. The company has a market cap of £215.40 billion, a PE ratio of 21.24, a price-to-earnings-growth ratio of 0.86 and a beta of 0.23. AstraZeneca has a twelve month low of GBX 9,573.51 and a twelve month high of £157.32.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.